HUTCHMED (China) (HCM) Revenue & Revenue Breakdown
HUTCHMED (China) Revenue Highlights
Latest Revenue (Y)
$838.00M
Latest Revenue (Q)
$152.56M
Main Segment (Y)
Other Collaboration Licensing Revenue
HUTCHMED (China) Revenue by Period
HUTCHMED (China) Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $838.00M | 96.52% |
| 2022-12-31 | $426.41M | 19.73% |
| 2021-12-31 | $356.13M | 56.21% |
| 2020-12-31 | $227.98M | 11.27% |
| 2019-12-31 | $204.89M | -4.31% |
| 2018-12-31 | $214.11M | -11.23% |
| 2017-12-31 | $241.20M | 11.63% |
| 2016-12-31 | $216.08M | 21.25% |
| 2015-12-31 | $178.20M | 94.09% |
| 2014-12-31 | $91.81M | 99.72% |
| 2013-12-31 | $45.97M | -76.47% |
| 2012-12-31 | $195.39M | 17.05% |
| 2011-12-31 | $166.92M | 24.10% |
| 2010-12-31 | $134.51M | 21.18% |
| 2009-12-31 | $111.00M | 27.62% |
| 2008-12-31 | $86.97M | 33.58% |
| 2007-12-31 | $65.11M | 29.10% |
| 2006-12-31 | $50.43M | 33.21% |
| 2005-12-31 | $37.86M | - |
HUTCHMED (China) generated $838.00M in revenue during NA 2023, up 96.52% compared to the previous quarter, and up 391.39% compared to the same period a year ago.
HUTCHMED (China) Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $152.56M | - |
| 2023-09-30 | $152.56M | -42.74% |
| 2023-06-30 | $266.44M | - |
| 2023-03-31 | $266.44M | 137.51% |
| 2022-12-31 | $112.18M | - |
| 2022-09-30 | $112.18M | 11.04% |
| 2022-06-30 | $101.02M | -26.88% |
| 2021-12-31 | $138.16M | 82.26% |
| 2021-06-30 | $75.81M | -7.05% |
| 2021-03-31 | $81.56M | 34.57% |
| 2020-12-31 | $60.61M | 9.80% |
| 2020-06-30 | $55.20M | 7.03% |
| 2020-03-31 | $51.57M | -2.41% |
| 2019-12-31 | $52.84M | 5.62% |
| 2019-06-30 | $50.03M | -4.10% |
| 2019-03-31 | $52.17M | 4.65% |
| 2018-06-30 | $49.85M | -4.75% |
| 2018-03-31 | $52.34M | -7.01% |
| 2015-12-31 | $56.28M | 0.15% |
| 2015-09-30 | $56.20M | 67.46% |
| 2014-12-31 | $33.56M | 20.18% |
| 2014-09-30 | $27.93M | - |
HUTCHMED (China) generated $152.56M in revenue during Q4 2023, up 0.00% compared to the previous quarter, and up 136.00% compared to the same period a year ago.
HUTCHMED (China) Revenue Breakdown
HUTCHMED (China) Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Other Collaboration Licensing Revenue | $278.86M | $14.95M | $23.66M | - | - |
| Other Collaboration Royalties Revenue | $32.47M | $26.31M | $15.06M | $4.89M | $2.65M |
| Research And Development Services | $481.00K | $507.00K | $525.00K | $491.00K | $494.00K |
| Collaboration Research And Development | $80.40M | $23.74M | $19.00M | $9.77M | $15.53M |
| Commercialization Services | $48.61M | $41.27M | $27.43M | $3.73M | $2.58M |
| Goods | - | $314.33M | $266.20M | - | - |
| Product | - | - | - | $203.61M | $175.99M |
HUTCHMED (China)'s latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Collaboration Licensing Revenue (63.26%), Collaboration Research And Development (18.24%), Commercialization Services (11.03%), Other Collaboration Royalties Revenue (7.37%), and Research And Development Services (0.11%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Jun 23 | Jun 22 | Jun 21 | Jun 20 | Dec 19 |
|---|---|---|---|---|---|---|
| Other Collaboration Licensing Revenue | $28.79M | $250.07M | $14.95M | - | - | - |
| Other Collaboration Royalties Revenue | $17.49M | $14.98M | $14.33M | $5.82M | $2.04M | $91.00K |
| Research And Development Services | $235.00K | $246.00K | $263.00K | $261.00K | $240.00K | $121.00K |
| Collaboration Research And Development | $51.68M | $28.72M | $12.34M | $4.79M | $7.51M | $5.06M |
| Commercialization Services | $23.25M | $25.36M | $21.59M | $15.03M | - | - |
| Seroquel | - | $1.10M | - | - | - | - |
| Product | - | - | $136.93M | $129.15M | $94.89M | $45.77M |
HUTCHMED (China)'s latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Collaboration Research And Development (42.56%), Other Collaboration Licensing Revenue (23.70%), Commercialization Services (19.15%), Other Collaboration Royalties Revenue (14.40%), and Research And Development Services (0.19%).
HUTCHMED (China) Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| HCM | HUTCHMED (China) | $838.00M | $152.56M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| RGC | Regencell Bioscience | - | - |
HCM Revenue FAQ
What is HUTCHMED (China)’s yearly revenue?
HUTCHMED (China)'s yearly revenue for 2023 was $838M, representing an increase of 96.52% compared to 2022. The company's yearly revenue for 2022 was $426.41M, representing an increase of 19.73% compared to 2021. HCM's yearly revenue for 2021 was $356.13M, representing an increase of 56.21% compared to 2020.
What is HUTCHMED (China)’s quarterly revenue?
HUTCHMED (China)'s quarterly revenue for Q4 2023 was $152.56M, a 0% increase from the previous quarter (Q3 2023), and a 36.00% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $152.56M, a -42.74% decrease from the previous quarter (Q2 2023), and a 36.00% increase year-over-year (Q3 2022). HCM's quarterly revenue for Q2 2023 was $266.44M, a 0% increase from the previous quarter (Q1 2023), and a 163.74% increase year-over-year (Q2 2022).
What is HUTCHMED (China)’s revenue growth rate?
HUTCHMED (China)'s revenue growth rate for the last 3 years (2021-2023) was 135.31%, and for the last 5 years (2019-2023) was 309.00%.
What are HUTCHMED (China)’s revenue streams?
HUTCHMED (China)'s revenue streams in c 23 are Other Collaboration Licensing Revenue, Other Collaboration Royalties Revenue, Research And Development Services, Collaboration Research And Development, and Commercialization Services. Other Collaboration Licensing Revenue generated $278.86M in revenue, accounting 63.26% of the company's total revenue, up 1764.75% year-over-year. Other Collaboration Royalties Revenue generated $32.47M in revenue, accounting 7.37% of the company's total revenue, up 23.41% year-over-year. Research And Development Services generated $481K in revenue, accounting 0.11% of the company's total revenue, down -5.13% year-over-year. Collaboration Research And Development generated $80.4M in revenue, accounting 18.24% of the company's total revenue, up 238.64% year-over-year. Commercialization Services generated $48.61M in revenue, accounting 11.03% of the company's total revenue, up 17.77% year-over-year.
What is HUTCHMED (China)’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of HUTCHMED (China) was Other Collaboration Licensing Revenue. This segment made a revenue of $278.86M, representing 63.26% of the company's total revenue.